CollPlant Biotechnologies (CLGN) Q4 2025 earnings summary

Executive summary

• Achieved a $2 million milestone payment from AbbVie for dermal filler development, expanding commercial reach in North America and Europe.

• Launched BioFlex, a ready-to-print rhCollagen kit for 3D bioprinting, and expanded distribution in the U.S. and Canada.

• Advanced regenerative breast implant program with promising preclinical results and no observed complications.

• Strengthened intellectual property with new patents in the U.S., South Korea, and Japan for dermal fillers and bioinks.

• Implemented a cost-reduction plan, reducing workforce by 25% and optimizing expenses.

Financial highlights

• GAAP revenues for 2025 were $2.4 million, up from $515,000 in 2024, mainly due to the AbbVie milestone.

• GAAP gross profit was $1.5 million in 2025, compared to a $1.1 million gross loss in 2024.

• GAAP operating expenses decreased to $13.0 million from $16.1 million year-over-year; non-GAAP operating expenses were $12.1 million.

• GAAP net loss narrowed to $11.5 million ($0.94/share) from $16.6 million ($1.45/share) in 2024; non-GAAP net loss was $10.2 million.

• Cash and cash equivalents at year-end 2025 were $5.6 million; cash used in operations was $9.4 million.

Outlook and guidance

• Plans to further optimize regenerative breast implants for long-term durability and tissue remodeling.

• Awaiting AbbVie’s review of interim clinical trial results to determine next steps in dermal filler collaboration.

• Focus on expanding clinical and commercial applications of rhCollagen platform in high-value markets.